rs1126744

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_004463.3(FGD1):​c.2136A>G​(p.Pro712Pro) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0454 in 1,190,574 control chromosomes in the GnomAD database, including 4,535 homozygotes. There are 16,461 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.14 ( 2127 hom., 4185 hem., cov: 21)
Exomes 𝑓: 0.036 ( 2408 hom. 12276 hem. )

Consequence

FGD1
NM_004463.3 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:7

Conservation

PhyloP100: -0.872

Publications

7 publications found
Variant links:
Genes affected
FGD1 (HGNC:3663): (FYVE, RhoGEF and PH domain containing 1) This gene encodes a protein that contains Dbl (DH) and pleckstrin (PH) homology domains and is similar to the Rho family of small GTP-binding proteins. The encoded protein specifically binds to the Rho family GTPase Cdc42Hs and can stimulate the GDP-GTP exchange of the isoprenylated form of Cdc42Hs. It also stimulates the mitogen activated protein kinase cascade leading to c-Jun kinase SAPK/JNK1 activation. Defects in this gene are the cause of the faciogenital dysplasia in Aarskog-Scott syndrome and a syndromatic form of X-linked cognitive disability. [provided by RefSeq, Jul 2017]
FGD1 Gene-Disease associations (from GenCC):
  • Aarskog-Scott syndrome, X-linked
    Inheritance: AD, XL Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), G2P, ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.96).
BP6
Variant X-54449671-T-C is Benign according to our data. Variant chrX-54449671-T-C is described in ClinVar as Benign. ClinVar VariationId is 95089.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-0.872 with no splicing effect.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.418 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
FGD1NM_004463.3 linkc.2136A>G p.Pro712Pro synonymous_variant Exon 14 of 18 ENST00000375135.4 NP_004454.2 P98174A0A024R9Y5

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
FGD1ENST00000375135.4 linkc.2136A>G p.Pro712Pro synonymous_variant Exon 14 of 18 1 NM_004463.3 ENSP00000364277.3 P98174

Frequencies

GnomAD3 genomes
AF:
0.140
AC:
15410
AN:
109762
Hom.:
2125
Cov.:
21
show subpopulations
Gnomad AFR
AF:
0.425
Gnomad AMI
AF:
0.00590
Gnomad AMR
AF:
0.0711
Gnomad ASJ
AF:
0.0156
Gnomad EAS
AF:
0.0977
Gnomad SAS
AF:
0.105
Gnomad FIN
AF:
0.0254
Gnomad MID
AF:
0.0812
Gnomad NFE
AF:
0.0191
Gnomad OTH
AF:
0.125
GnomAD2 exomes
AF:
0.0670
AC:
11999
AN:
179080
AF XY:
0.0587
show subpopulations
Gnomad AFR exome
AF:
0.441
Gnomad AMR exome
AF:
0.0350
Gnomad ASJ exome
AF:
0.0145
Gnomad EAS exome
AF:
0.0962
Gnomad FIN exome
AF:
0.0283
Gnomad NFE exome
AF:
0.0185
Gnomad OTH exome
AF:
0.0464
GnomAD4 exome
AF:
0.0358
AC:
38667
AN:
1080756
Hom.:
2408
Cov.:
28
AF XY:
0.0352
AC XY:
12276
AN XY:
348276
show subpopulations
African (AFR)
AF:
0.432
AC:
11119
AN:
25759
American (AMR)
AF:
0.0391
AC:
1372
AN:
35064
Ashkenazi Jewish (ASJ)
AF:
0.0183
AC:
351
AN:
19143
East Asian (EAS)
AF:
0.0887
AC:
2671
AN:
30106
South Asian (SAS)
AF:
0.0950
AC:
5061
AN:
53285
European-Finnish (FIN)
AF:
0.0277
AC:
1122
AN:
40443
Middle Eastern (MID)
AF:
0.0585
AC:
232
AN:
3966
European-Non Finnish (NFE)
AF:
0.0167
AC:
13825
AN:
827524
Other (OTH)
AF:
0.0641
AC:
2914
AN:
45466
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.446
Heterozygous variant carriers
0
1022
2045
3067
4090
5112
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
778
1556
2334
3112
3890
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.141
AC:
15431
AN:
109818
Hom.:
2127
Cov.:
21
AF XY:
0.130
AC XY:
4185
AN XY:
32130
show subpopulations
African (AFR)
AF:
0.424
AC:
12690
AN:
29906
American (AMR)
AF:
0.0710
AC:
731
AN:
10295
Ashkenazi Jewish (ASJ)
AF:
0.0156
AC:
41
AN:
2620
East Asian (EAS)
AF:
0.0974
AC:
336
AN:
3450
South Asian (SAS)
AF:
0.104
AC:
266
AN:
2548
European-Finnish (FIN)
AF:
0.0254
AC:
149
AN:
5868
Middle Eastern (MID)
AF:
0.0837
AC:
18
AN:
215
European-Non Finnish (NFE)
AF:
0.0191
AC:
1006
AN:
52744
Other (OTH)
AF:
0.127
AC:
190
AN:
1494
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
349
697
1046
1394
1743
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
148
296
444
592
740
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.117
Hom.:
3495
Bravo
AF:
0.159

ClinVar

Significance: Benign
Submissions summary: Benign:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:3
Dec 28, 2018
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

p.Pro712Pro in exon 14 of FGD1: This variant is not expected to have clinical significance because it does not alter an amino acid residue, is not located within the splice consensus sequence, and has been identified in 44.23% (3737/8449) of African chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs1126744). -

-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Nov 16, 2012
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:3
Feb 02, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

May 04, 2021
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Inborn genetic diseases Benign:1
Dec 13, 2014
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.96
CADD
Benign
1.1
DANN
Benign
0.46
PhyloP100
-0.87
Mutation Taster
=98/2
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1126744; hg19: chrX-54476104; COSMIC: COSV64309403; COSMIC: COSV64309403; API